Internal Medicine · 2022 · 10 citations · 10 references
Life SciencesImmunologyOncologyCancer ImmunologyClinical ImmunologyImmunotherapyAutoimmune DiseasesCheckpoint Inhibitor TherapyImmune CheckpointsImmune-related Adverse EventsLambert-eaton Myasthenic SyndromeLung CancerHigh-frequency StimulationImmune Checkpoint Inhibitor TherapyImmune-related Adverse Event AssessmentLambert-eaton Myasthenic Syndrome PharmacotherapyNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentVoltage-gated Calcium Channels
A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor, the patient complained of muscle weakness, fatigue, ptosis, and dysarthria. The anti-voltage-gated calcium channel antibody level was elevated, and waxing was observed on a high-frequency repetitive stimulation test using an electromyogram. We diagnosed her with recurrence of LEMS as an immune-related adverse event (irAE) induced by pembrolizumab. After intravenous immunoglobulin therapy, the patient's symptoms improved, and she was discharged.
10